Journey Medical’s (DERM) Buy Rating Reiterated at HC Wainwright

Journey Medical (NASDAQ:DERM)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $13.00 price target on the stock. HC Wainwright‘s target price would indicate a potential upside of 161.62% from the stock’s current price. HC Wainwright also issued estimates for Journey Medical’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.15 EPS, FY2028 earnings at $0.45 EPS, FY2029 earnings at $0.66 EPS and FY2030 earnings at $0.72 EPS.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research note on Thursday, October 15th. B. Riley Financial restated a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Journey Medical in a report on Thursday, August 13th. Finally, Wall Street Zen lowered shares of Journey Medical from a “buy” rating to a “hold” rating in a report on Saturday, October 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Journey Medical currently has an average rating of “Hold” and an average price target of $14.00.

Journey Medical Price Performance

NASDAQ DERM traded up $0.01 on Monday, reaching $4.97. The stock had a trading volume of 14,727 shares, compared to its average volume of 214,434. The business’s 50-day moving average price is $6.62 and its 200 day moving average price is $6.70. Journey Medical has a 12-month low of $4.31 and a 12-month high of $9.56.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. The business had revenue of $18.51 million during the quarter, compared to analyst estimates of $18.36 million. On average, research analysts forecast that Journey Medical will post -0.02 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Punch & Associates Investment Management Inc. acquired a new position in Journey Medical in the 2nd quarter valued at about $3,795,000. J. Goldman & Co LP purchased a new stake in shares of Journey Medical in the second quarter worth about $974,000. Wasatch Advisors LP raised its stake in shares of Journey Medical by 34.0% in the 2nd quarter. Wasatch Advisors LP now owns 2,858,930 shares of the company’s stock valued at $20,241,000 after purchasing an additional 725,560 shares in the last quarter. BlackRock Inc. bought a new position in shares of Journey Medical during the second quarter worth about $715,000. Finally, Bank of America Corp DE bought a new stake in shares of Journey Medical in the 2nd quarter worth approximately $297,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing prescription products for medical dermatology. The company targets conditions that affect the skin, hair and nails, with an emphasis on products that address significant patient needs and can be marketed through its specialty sales organization.

Its portfolio includes Qbrexza (glycopyrronium) cloth, a topical treatment for primary axillary hyperhidrosis, and Targadox (doxycycline hyclate) delayed-release capsules, which are used to treat moderate-to-severe inflammatory acne vulgaris.